Physician profile
Helen Patzanakidis
NPI 1639288368
$5,508.43
in general payments reported to CMS, 2019-2025
38 companies · $793 in 2025
The $793 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $902 · 2020: $581 · 2021: $926 · 2022: $668 · 2023: $707 · 2024: $932 · 2025: $793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,432.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,431.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $734.55 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $598.02 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $475.61 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $390.35 | 2019-2023 | Steglatro, Belsomra |
| Abbott Laboratories | $310.33 | 2022-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $291.19 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $274.02 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Pfizer INC. | $265.39 | 2019-2025 | |
| Astellas Pharma US INC | $254.55 | 2019-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $232.15 | 2020-2024 | Jardiance |
| Amgen INC. | $204.06 | 2019-2025 | Repatha, Otezla, Repatha |
| Eisai INC. | $138.77 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $131.68 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $123.57 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $103.65 | 2025 | Gemtesa, Myfembree |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Helen Patzanakidis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.